StockNews.com began coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Free Report) in a research report released on Monday. The brokerage issued a hold rating on the medical research company’s stock.
Accelerate Diagnostics Stock Down 1.1 %
Shares of AXDX opened at $1.77 on Monday. The stock has a market cap of $39.03 million, a PE ratio of -0.43 and a beta of 0.61. Accelerate Diagnostics has a 12-month low of $0.73 and a 12-month high of $6.39. The business has a 50-day simple moving average of $1.75 and a two-hundred day simple moving average of $1.35.
Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.05. The firm had revenue of $2.99 million during the quarter, compared to analyst estimates of $3.00 million. On average, equities research analysts expect that Accelerate Diagnostics will post -2.14 EPS for the current year.
Institutional Inflows and Outflows
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Further Reading
- Five stocks we like better than Accelerate Diagnostics
- What is Short Interest? How to Use It
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How Can Investors Benefit From After-Hours Trading
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.